Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. officer Daniel Rabinowitz, the company’s Secretary and Chief Legal Officer, reported selling 1,334 shares of Natera common stock on February 3, 2026 at a price of $230.768 per share. After this transaction, he beneficially owned 223,813 shares directly.
The filing explains that the sale was carried out to cover tax withholding and remittance obligations arising from the vesting of restricted stock units (RSUs). It was executed under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, indicating it was a pre-arranged, rule-compliant sale plan linked to prior equity grants.
Natera, Inc. reported that its President and Chief Business Officer, John Fesko, received an award of 6,135 restricted stock units (RSUs) of Natera common stock on January 30, 2026. These RSUs vested immediately upon issuance, and each RSU represents one share of common stock.
Following this equity grant, Fesko directly beneficially owns 181,675 shares of Natera common stock. The transaction was recorded at a price of $0.00 per share, reflecting a compensatory stock award rather than an open-market purchase.
Natera, Inc. director received 73 shares of common stock on January 30, 2026 through an award of restricted stock units (RSUs) granted in lieu of a $17,500 quarterly cash retainer for Board service.
The RSUs were fully vested at issuance, and each RSU converts into one share of Natera common stock. Following this grant, the director directly holds 5,389 shares of Natera common stock.
Natera, Inc. director Herm Rosenman reported a stock-based board fee. On 01/30/2026 he received 99 shares of Natera common stock through fully vested Restricted Stock Units granted in lieu of a quarterly board retainer of $23,750.
Each RSU represents one share of Natera common stock, so the grant directly increased his holdings. After this transaction, Rosenman beneficially owned 20,441 shares of Natera common stock held directly.
Natera, Inc. director Marcus Gail Boxer received an award of 91 restricted stock units on 01/30/2026 as part of his Board compensation. The RSUs were issued in lieu of quarterly retainer fees of $21,875 and were fully vested at issuance.
Each RSU represents a right to receive one share of Natera common stock. Following this grant, Boxer beneficially owned 5,853 shares of Natera common stock in direct ownership.
Natera director Rowan E. Chapman received equity compensation for board service. On 01/30/2026, Chapman was awarded 97 restricted stock units (RSUs) in lieu of a quarterly cash retainer of $23,125 for serving on Natera’s Board of Directors. The RSUs were fully vested at issuance, and each RSU represents one share of Natera common stock. Following this grant, Chapman directly beneficially owned 5,874 shares of Natera common stock.
Natera, Inc. director Roelof Botha received equity compensation for board service. On January 30, 2026, he was issued 112 Restricted Stock Units (RSUs) in lieu of a quarterly cash retainer of $26,875 for serving on Natera's Board of Directors. The RSUs were fully vested at issuance, and each RSU represents a right to receive one share of Natera common stock. Following this grant, Botha directly beneficially owned 2,540 shares of Natera common stock and indirectly beneficially owned 1,154,198 shares through estate planning vehicles.
Natera director Monica Bertagnolli received equity compensation instead of cash fees. On 01/30/2026 she was issued 70 Restricted Stock Units (RSUs) in lieu of a quarterly board retainer of $16,875. The RSUs were fully vested at issuance and each RSU equals one share of Natera common stock, bringing her directly held beneficial ownership to 5,291 shares.
Natera, Inc. director equity compensation filing: Director Roy D. Baynes received 70 shares of Natera common stock on 01/30/2026, reported as an acquisition under code "A". These shares were issued as Restricted Stock Units in lieu of a quarterly board retainer of $16,875.
The RSUs were fully vested at the time of issuance, and each RSU represents a right to receive one share of Natera common stock. Following this award, Baynes beneficially owns 18,429 shares of Natera common stock, held in direct ownership.
An affiliate of the issuer, Michael Brophy, filed a Form 144 notice to sell 5,671 shares of common stock through Morgan Stanley Smith Barney on NASDAQ. These shares were acquired as restricted stock units on 09/28/2025, when payment was recorded as non-cash (N/A).
The filing notes that 138,014,465 common shares were outstanding and lists several sales during the prior three months, including transactions under a Rule 10b5-1 sales plan and direct sales, with individual trades as large as 36,573 and 23,948 shares of common stock.